EGFR and non-small cell lung carcinoma: The overall frequency (22.2%) of MET GCN gain in our cohort of EGFR-mutated cases was similar to that reported by Schildhaus et al. in their overall NSCLC population and subgroup of EGFR-mutated tumors [11].